SESSION TYPE: ARDS/Lung Injury Posters
PRESENTED ON: Wednesday, October 24, 2012 at 01:30 PM - 02:30 PM
PURPOSE: Neutropenia recovery is associated with deterioration in oxygenation and exacerbation of pre-existing pulmonary disease. We aimed to evaluate effect of imatinib and nilotinib on lipopolysaccharide (LPS) - induced acute lung injury (ALI) during neutropenia recovery in a mouse model.
METHODS: We developed a mouse model of ALI during neutropenia recovery. Cyclophosphamide was administrated to induce neutropenia. During neutropenia recovery, ALI was induced by intratracheal instillation of LPS. Imatinib or nilotinib was administrated during neutropenia recovery.
RESULTS: The numbers of inflammatory cells and neutrophil in bronchoalveolar lavage fluid in imatinib or nilotinib group were significatly lower than LPS group. Imatinib or nilotinib administration significantly reduced wet/dry ratio and ALI score. The levels of myeloperoxidase, tumor necrosis factor-α, IL-6, and IL-1β in imatinib or nilotinib group were significantly lower than LPS group. Attenuation of ALI by imatinib or nilotinib was associated with PDGFRβ and C-kit pathway.
CONCLUSIONS: Imatinib or nilotinib effectively attenuated LPS-induced ALI during neutropenia recovery.
CLINICAL IMPLICATIONS: Imatinib and nilotinib can be effective on patients with ALI during neutropenia. Further study about the effect of imatinib and nilotinib on patients with ALI during neutropenia is needed.
DISCLOSURE: The following authors have nothing to disclose: Jongmin Lee, Chin Rhee, Jin Kim, Sang Lee
No Product/Research Disclosure InformationSeoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea